Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21051896 | 0.80 | KMT2A (0.36) | KMT2AMEN1ALDH1A1PKMCYP1A2 | |
| SCHEMBL12551017 | 0.78 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL896956 | 0.77 | KMT2A (0.37) | KMT2AMEN1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25431154 | 0.75 | ALDH1A1 (0.44) | ALDH1A1PKMCYP1A2POLB | |
| SCHEMBL312073 | 0.75 | ALDH1A1 (0.44) | ALDH1A1PKMCYP1A2POLB | |
| SCHEMBL3770379 | 0.74 | — | — | |
| SCHEMBL25433068 | 0.74 | POLB (0.48) | KMT2AALDH1A1PKMPOLB | |
| SCHEMBL1037242 | 0.72 | HRH3 (0.48) | KMT2AALDH1A1PKMCYP1A2POLB | |
| SCHEMBL25432585 | 0.72 | HRH3 (0.48) | KMT2AALDH1A1PKMCYP1A2POLB | |
| SCHEMBL20858732 | 0.72 | HRH3 (0.48) | KMT2AALDH1A1PKMCYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | KMT2A 4010/4885MEN1 272/4885ALDH1A1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.